Chemo's hidden toll on blood vessels revealed
NCT ID NCT04042298
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study measured blood flow in the skin of 62 people, including cancer patients who received 5-FU chemotherapy, those on other treatments, cancer survivors, and healthy controls. Researchers used a non-invasive laser sensor to see how small blood vessels responded to substances that widen or narrow them. The goal was to understand why 5-FU can cause heart problems.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help explain how 5-FU chemotherapy affects blood vessels, potentially leading to better monitoring or prevention of heart-related side effects.
- What could go wrong
- This is a small, completed observational study that only measures blood flow at one time point. It does not test any treatment, so it cannot directly improve patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
62 people
The number who actually took part.
- Started
-
Jun 2019
- Finished
-
Jun 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Newly diagnosed cancer patients who have received (or are scheduled to receive) 5-FU chemotherapy within the past 30 days (n=26) will enter the study soon after initiation of treatment. Newly diagnosed cancer patients receiving cancer treatment other than 5-FU (n=26; chemotherapy, radiotherapy, etc.) will enter into the study soon after initiation of treatment. Cancer survivors (n=26) who have previously received 5-FU but not within the year proceeding enrollment will be entered into the study. Age, sex, and health (n=26; excluding cancer) matched controls will be included in the study.
- Ages
-
21 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Give voluntary consent to participate in the study * (Group 1) Current cancer treatment includes 5-FU * (Group 2) Current cancer treatment does not include 5-FU * (Group 3) Cancer survivor previously treated with 5-FU but has not received cancer treatment in the year proceeding enrollment. * (Group 4) Age, sex, and health matched (excluding cancer) control for Group 1 Exclusion Criteria: * (Groups 1, 2, and 4) Have received cancer treatment outside of the past year * Not met above criteria * Pregnant, breastfeeding, or planning to become pregnant * Unable to provide informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for 5-fluorouracil toxicity are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lafene Health Center
Manhattan, Kansas, 66502, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- Can a dental assistant keep cancer Patients' mouths healthier during radiation?
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?